OMHealthcare · Medical DevicesThe 3 Wall Street analysts covering Outset Medical, Inc. hold a median 12-month price target of $7 — +40.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Outset Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (89): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (3): The shares have been drifting down relative to others.
The rank is the raw material. Whether the rules would actually own Outset Medical, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on OM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +40.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Feb 2026 | BTIG | Maintains | Buy | $17 → $15 |
| 7 Jan 2026 | Stifel | Maintains | Buy | — |
| 16 Dec 2025 | BTIG | Reiterates | Buy | — |
| 11 Nov 2025 | BTIG | Maintains | Buy | — |
| 11 Nov 2025 | RBC Capital | Maintains | Sector Perform | — |
| 11 Nov 2025 | Stifel | Maintains | Buy | — |
| 19 Aug 2025 | RBC Capital | Reiterates | Sector Perform | — |
| 7 Aug 2025 | RBC Capital | Maintains | Sector Perform | — |
| 21 May 2025 | RBC Capital | Maintains | Sector Perform | — |
| 8 May 2025 | RBC Capital | Maintains | Sector Perform | — |
| 7 Jan 2025 | RBC Capital | Reiterates | Sector Perform | — |
| 8 Aug 2024 | RBC Capital | Downgrade | Sector Perform | — |
| 8 Aug 2024 | TD Cowen | Maintains | Buy | — |
| 21 June 2024 | RBC Capital | Upgrade | Outperform | — |
| 8 Apr 2024 | BTIG | Initiates | Buy | — |
| 12 Jan 2024 | RBC Capital | Downgrade | Sector Perform | — |
| 4 Dec 2023 | Morgan Stanley | Maintains | Equal-Weight | — |
| 14 Nov 2023 | Morgan Stanley | Maintains | Equal-Weight | — |
| 13 Oct 2023 | B of A Securities | Downgrade | Underperform | — |
| 13 Oct 2023 | RBC Capital | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 81% of US stocks
Cheaper than 77% of US stocks
Cheaper than 79% of US stocks
Cheaper than 64% of US stocks
Higher than 20% of US stocks
Higher than 29% of US stocks
Higher than 56% of US stocks
Higher than 16% of US stocks
Higher than 8% of US stocks
Higher than 20% of US stocks
Higher than 23% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OM appears on the weeks it earns a place.
A law firm is urging Outset Medical, Inc. shareholders to contact them regarding potential breaches of fiduciary duties by company insiders, offering to handle the matter on a contingent fee basis.
Why it matters — OM watchers should note this because it raises the possibility of legal action against the company's leadership for alleged misconduct toward shareholders.
The 3 Wall Street analysts covering Outset Medical, Inc. have a median 12-month price target of $7, with estimates ranging from $6 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Outset Medical, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Outset Medical, Inc. 36 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, Outset Medical, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (89 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +40.3% from the last close, and Ticker Nerd's factor model ranks Outset Medical, Inc. 36 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Outset Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $10 over the next 12 months.
Outset Medical, Inc. returned -66.8% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Outset Medical Inc. is a pioneering company in the medical technology field, primarily focusing on the development and commercialization of innovative dialysis solutions.
The most recent item we track (PRNewsWire, 29 July 2026): "Did Outset Medical, Inc. Insiders Breach their Fiduciary Duties to Shareholders?". A law firm is urging Outset Medical, Inc. shareholders to contact them regarding potential breaches of fiduciary duties by company insiders, offering to handle the matter on a contingent fee basis.
Outset Medical Inc. is a pioneering company in the medical technology field, primarily focusing on the development and commercialization of innovative dialysis solutions. Its flagship product, the Tablo Hemodialysis System, is designed to simplify dialysis treatments, whether in medical facilities or at home. The system integrates water purification with dialysate production, offering a seamless, all-in-one dialysis solution. This transformative approach aims to make dialysis more accessible and user-friendly for patients and healthcare providers. Outset Medical's advancements in the dialysis sector are significant, as they strive to redefine treatment standards and improve patient quality of life. Headquartered in the United States, Outset Medical continues to impact the healthcare industry by addressing the growing demand for efficient and scalable renal care solutions.
CEO Ms. Leslie L. Trigg · 310 employees · United States · https://www.outsetmedical.com